logo-loader

VolitionRX Ltd to present at colorectal cancer meeting

Last updated: 09:30 19 May 2016 EDT, First published: 04:30 19 May 2016 EDT

Cancer screening.
The key objectives of the WEO CRC meeting are to provide updates on recent advances in colorectal cancer screening

VolitionRx Ltd (NYSEMKT:VRNX), a specialist in blood-based diagnostic tests, is to present at a meeting of colorectal cancer experts on Friday, 20 May.

The company's chief medical officer, Dr Jason Terrell, is to present at the World Endoscopy Organization (WEO) Colorectal Screening Committee (CRC) meeting, ahead of the start of the Digestive Disease Week (DDW) conference, which kicks off in San Diego on Saturday.

Dr Terrell, who is also head of VolitionRX's US operations, will present data from three clinical trials evaluating the company's NuQ blood tests.

The presentation will include three data sets: results from the its first completed prospective clinical trial in colorectal cancer; results from its first completed retrospective clinical trial targeted at detecting adenomas, or benign tumours that may affect various organs; and interim results from a retrospective study of 4,800 patients at Hvidovre Hospital.

“To date, VolitionRx has demonstrated across several clinical trials that our NuQ blood test is able to accurately detect colorectal cancer with high sensitivity and specificity, as well as further distinguish between cancer, adenomas and healthy subjects. We believe we have a very promising test for accurately diagnosing CRC [colorectal cancer] through a non-invasive, affordable method that can be performed on a small amount of blood collected in a routine blood draw," Dr Terrell said.

The key objectives of the WEO CRC meeting are to provide updates on recent advances in colorectal cancer screening, seek advice and comments on future initiatives, and reach consensus on controversial areas.

Digestive Disease Week is the world's largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour, 36 minutes ago